Leen Kawas has spent her career at the intersection of science, entrepreneurship, and ethics—building companies where innovation serves both the patient and the portfolio. As CEO of EIT Pharma, board member at Inherent Biosciences, and managing general partner of Propel Bio Partners, Kawas has helped shape a new generation of biotech ventures defined by purpose as much as performance. Her guiding conviction is simple yet profound: the strongest financial returns emerge when business goals are aligned with meaningful clinical impact.
Kawas’s philosophy is rooted in experience. As the co-founder and former CEO of Athira Pharma, she led one of the few biotech companies founded by a woman to go public, raising over $400 million in 2020. But what distinguished her leadership wasn’t the milestone itself—it was her approach to value creation. She saw no contradiction between advancing shareholder interests and improving patient lives. Instead, she treated the two as interdependent. “Biotech succeeds,” she has often explained, “when innovation meets integrity.”
Her view challenges a persistent tension in the life sciences industry: the perceived trade-off between profitability and patient-centered innovation. Too often, companies face pressure to accelerate timelines or prioritize investor sentiment at the expense of long-term outcomes. Kawas believes this short-termism undermines both mission and market stability. A breakthrough drug that truly improves lives, she argues, doesn’t just generate goodwill—it builds enduring commercial value by addressing real, unmet needs.
At Propel Bio Partners, the venture fund she co-founded, this philosophy is built into the investment model. The firm backs entrepreneurs who approach science with rigor and empathy—founders who see patients not as data points but as partners in discovery. Leen Kawas focuses on identifying companies with both strong scientific underpinnings and a clear path to measurable health outcomes. For her, due diligence is as much about character as chemistry. Teams that internalize patient focus, she notes, tend to make more disciplined, data-driven decisions that de-risk both the science and the investment.
She also advocates for deeper collaboration between investors and scientists. In Kawas’s view, the traditional gap between the lab and the boardroom often leads to misaligned incentives. When financial stakeholders understand the scientific process—and when researchers appreciate the realities of capital deployment—innovation can move forward with clarity and confidence. Her leadership across companies demonstrates how shared literacy between these worlds fosters smarter risk-taking and more resilient business models.
Underlying this approach is a belief in long-horizon thinking. Kawas often notes that life sciences breakthroughs cannot be rushed without consequence. Drug development timelines are inherently uncertain, but when guided by transparency, rigorous trial design, and ethical decision-making, they can deliver both sustainable profits and societal benefit. The key, she argues in this interview on Principal Post, lies in patience backed by precision—funding teams that manage uncertainty through evidence, not expedience.
This commitment to alignment extends beyond individual companies to the ecosystem as a whole. Through Propel, Kawas supports diverse founders and underrepresented voices in biotech—those who bring new perspectives to old problems. She views inclusivity not only as a moral imperative but as a strategic one. Broader participation, she believes, expands the frontier of discovery, leading to therapies that serve wider populations and ultimately deliver broader market returns. In her model, equity and innovation reinforce each other.
Kawas’s leadership style reflects the same integration she promotes in her businesses: analytical yet empathetic, disciplined yet visionary. Colleagues describe her as someone who sees connections others miss—between molecules and markets, between finance and ethics, between data and dignity. Her approach redefines success in biotechnology as a multi-dimensional equation, where profit, purpose, and progress must balance.
In conversations about the future of biotech investing, Kawas frequently returns to one idea: sustainability through trust. When companies prioritize patient outcomes, they build credibility with regulators, physicians, and investors alike. That trust compounds over time, yielding stronger partnerships and more predictable growth. In a sector where volatility is the norm, she sees integrity as the most undervalued asset on the balance sheet.
Through her work at EIT Pharma, Inherent Biosciences, and Propel Bio Partners, Leen Kawas continues to demonstrate how aligning investor returns with patient outcomes is not just ethical leadership—it is strategic foresight. By grounding innovation in empathy and execution in evidence, she’s helping shape a biotechnology landscape where doing good and doing well are finally part of the same formula. Her vision offers a blueprint for an industry ready to measure success not only in market capitalization, but in lives transformed.
Learn more about Leen Kawas’ work at EIT Pharma at the link below: